Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02256397
Other study ID # HSC-MS-14-0380
Secondary ID UL1TR000371KL2TR
Status Completed
Phase N/A
First received September 30, 2014
Last updated May 3, 2017
Start date October 2014
Est. completion date April 2017

Study information

Verified date May 2017
Source The University of Texas Health Science Center, Houston
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess whether comprehensive care enhanced with new technology to optimize asthma care in the home (using both a special sensor to track inhaler use and a hand-held PIKO-1 device to assess patients' forced expiratory volume in the 1st second [FEV1]) is effective in reducing total days when medical treatment is given outside the home (in clinic, emergency department, or hospital) among children with severe asthma receiving comprehensive care.


Description:

BACKGROUND INFORMATION

Asthma is the most common pediatric chronic disease. Despite the understanding of its pathophysiology and the availability of effective therapies, adverse effects on health, school attendance, academic achievement, and family life remain high, particularly among children with severe asthma in minority or low income families.

Innovative new approaches are needed. One innovation that have shown to be cost-effective in high-risk chronically ill children, including children with severe asthma, is care in an enhanced medical home, our High-Risk Comprehensive Care (HRCC) which was designed to optimize care in medical settings. The innovation to be pilot-tested in the proposed research is Home-Centered Comprehensive Care (HCCC) designed to also optimize care in the home and thereby reduce clinic visits and school absences and further decrease Emergency Department visits and hospital days. The proposed HCCC trial builds on the infrastructure, cell phone access to the child's primary caregivers at any hour, and improved outcomes established in our previous HRCC trial (clinicaltrials.gov Identifier: NCT02128776.

DESIGN

Pilot trial of 80 children (2-18 years of age) with uncontrolled severe asthma randomized to either:

- High-Risk Comprehensive Care (HRCC) that includes 24/7 cell phone access to skilled caregivers, same day care for acute illness Monday through Friday, subspecialty care available in the same facility, and identification each weekday of all children having ED visits and hospitalizations to assure prompt follow-up and coordination of care; or

- Home-Centered Comprehensive Care (HCCC) that will also include: 1) monitoring and augmenting treatment adherence using a special sensor to track inhaler use and identify inadequate or excessive medication; 2) using a simple hand-held PIKO-1 device to assess and transmit to caregivers the 1-second forced expiratory volume, allowing caregivers to better assist the parents and to make better treatment decisions and gauge response at any hour.

HYPOTHESES

HCCC will be associated with:

1. A >40% reduction in treatment days outside the home (in a clinic, ED visits or hospital) per child-year from enrollment to the end of the trial (primary hypothesis);

2. A decrease in school absences with respiratory problems to <5 d per school year;

3. An increase in FEV1>12% in routine pulmonary function tests in our clinic at 12 mo. after enrollment;

4. Increased maternal satisfaction on the Consumer Assessment of Healthcare Providers and Systems Survey;

5. Reduced or low net health system costs relative to that reported for common treatment methods for asthma (expressed as health system cost per clinic visit, ED visit, hospitalization, or school absence prevented);

6. Reduced Medicaid costs (due to lower reimbursements for clinic, ED, and hospital care);

7. An increase in medical school costs relative to reimbursements that will be lower than the savings to Medicaid (due to its reduction in reimbursements). Such a difference will be important in efforts to promote adequate reimbursements for such care to the medical school

OBJECTIVES:

1.To randomize 80 eligible children to either standard HRCC or to HCCC in addition to HRCC in a pilot trial and evaluate whether the augmentation of the HCCC program will:

1. reduce total days when medical treatment is given outside the home (in a clinic, ED, or hospital);

2. reduce days of school missed with respiratory illnesses (including respiratory infections with symptoms aggravated by asthma);

3. improve routine pulmonary function tests one year after enrollment;

4. augment maternal satisfaction of care above even the high current levels for CC;

5. reduce costs from a health system perspective and government (Medicaid) perspective

6. increase costs relative to reimbursements from the provider (medical school) perspective

STUDY DESIGN:

Pilot trial of 80 severe asthmatics attending the HRCC that includes 24/7 cell phone access to skilled primary caregivers or to HRCC with the addition of HCCC that will also include: 1) monitoring and augmenting treatment adherence using a special sensor to track inhaler use and identify inadequate or excessive medication; 2) using a simple hand-held PIKO-1 device to assess and transmit to caregivers the 1-second forced expiratory volume, allowing caregivers to better assist the parents and to make better treatment decisions and gauge response at any hour.

The pilot trial will have duration of 2 years. We will measure efficacy based on increase FEV1 in routine pulmonary function test, reduced total days spent in clinics, Emergency departments and hospital, and well as reduced total days of school missed due to pulmonary illness. Safety will be assessed by looking at any unexpected adverse events.

With parental consent, we can also augment our care through use of Linked In to visualize the child and assess his/her condition. We recently surveyed our asthma patients given CC and to our surprise found that 75% (30/42) have access to "Linked in" on their home computer or smart phone.


Recruitment information / eligibility

Status Completed
Enrollment 63
Est. completion date April 2017
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender All
Age group 2 Years to 18 Years
Eligibility Inclusion Criteria:

- Children with severe asthma (poorly controlled by NIH guidelines ) who meet the inclusion criteria for HRCC (>3 ED visits, >2 hospitalizations, or >1 pediatric ICU admission in past as well as a >50% estimated risk of hospitalization in next yr).

Exclusion Criteria:

- other major lung disease (e.g. cystic fibrosis or bronchopulmonary dysplasia) or neuromuscular impairment.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Standard comprehensive care
Standard comprehensive care at High Risk Children's Clinic
enhanced comprehensive care
standard comprehensive care at the High Risk Children's Clinic enhaced with new technologies: If between 2 and 5 years old--> will receive Home-centered comprehensive care with the propeller 5 and above--> will receive home-centered comprehensive care with propeller and PIKO

Locations

Country Name City State
United States High Risk Children's Clinic Houston Texas

Sponsors (3)

Lead Sponsor Collaborator
The University of Texas Health Science Center, Houston Centers for Medicare and Medicaid Services, National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Medical treatment outside of home Total number of days when medical treatment was given outside the home (in a clinic, ED, or hospital).
Measured by parent report every 3 months for both groups.
2 years
Secondary Days of missed school Total number of days of school missed with respiratory illnesses (including respiratory infections with symptoms aggravated by asthma).
Measured by parental report on questionnaires given every 3 months
2 years
Secondary Pulmonary Function Tests. (PFTs) Improve routine pulmonary function tests one year after enrollment by measuring PFTs during every clinic visit (for both groups), and by hand-held PFT device (PiKo-only for intervention group) 2 years
Secondary Parental Satisfaction Parental satisfaction among groups using CAHPS survey annually. 2 years
Secondary Total costs of clinic and hospital care Total cost of clinic and hospital cost measured using billing information. 2 years
Secondary Physician Services Cost to Reimbursement Physician Services cost to reimbursement measured using UT claims data. 2 years
See also
  Status Clinical Trial Phase
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device